The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.
This is due to the availability of strategies to successfully engineer antibodies into humanized forms, better understanding of the biological processes involved in cancer development, the availability of novel recombinant antibody formats, better antibody selection platforms, and improved antibody conjugation methodologies.
Attracting the attention of academia and industrial researchers, several polymer conjugation methodologies have been shown to have a wide range of applications and a success rate that have been confirmed by the numerous conjugates already in clinical use or under investigation in on-going clinical trials.
In order to for them to be used clinically, however, a final targeting liposome construct will need to be selected after each component, i.e. peptide ligands, conjugation methodologies, and liposomal drugs, have been optimized.
In order to explore the use of diverse and biologically complex targeting ligands, new conjugation methodologies have been developed for SCKs.
CRRL is a general methodology for conjugation and release and will be a useful tool for scientists and engineers in various fields aiming to design smart molecules and materials, which alter their biological activities according to specific changes in their physiological environments, or for material science applications.
In contrast to previous methodology, the direct conjugation to the nucleobase 5-position allows greater flexibility in the incorporated structure.
The reported cross-coupling methodology is orthogonal to many reported conjugation methods and supplements these to enable the introduction of multiple different modifications.
The T45A-D46A mutation was transferred from the suicide vector down to the virulence plasmid by conjugation and double cross-over performed using previously reported methodology [65].
